Zydus and Torrent Pharma Sign Licensing Deal for Semaglutide in India

Zydus Lifesciences Ltd and Torrent Pharmaceuticals Ltd have signed a licensing agreement to co-market the Semaglutide Injection in India. The agreement allows Zydus to manufacture and supply the product, while Torrent Pharma will co-market it under its brand name SEMBOLICTM. Zydus will market the product under the brand names SEMAGLYNTM, MASHEMATM, and ALTERMETM. The Semaglutide Injection is designed for the treatment of adults with insufficiently controlled type 2 diabetes mellitus and for chronic weight management.

Under the terms of the agreement, Torrent Pharma will pay an upfront licensing fee to Zydus. The financial specifics of the licensing fee have not been disclosed in the filing. Torrent Pharma has received semi-exclusive rights to co-market the product in India, leveraging its strong presence in chronic therapies and extensive field force across the country. This financial arrangement is expected to facilitate the distribution and marketing of the Semaglutide Injection across India.

The Semaglutide Injection developed by Zydus is an innovative formulation (15 mg/3 ml) in a prefilled cartridge, administered using a reusable pen device. This device is designed to deliver all strengths for both indications through a single platform, aiming to enhance patient convenience and improve treatment adherence. The injection is indicated for adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise, either as monotherapy or in addition to other medicinal products. It is also indicated for chronic weight management in adults with a BMI of ≥30 kg/m² or ≥27 kg/m² with weight-related comorbidities.

The partnership between Zydus and Torrent Pharma aims to expand access to advanced GLP-1 therapies for metabolic disorders in India. This collaboration combines Zydus’s product development and manufacturing capabilities with Torrent Pharma’s market expertise. The agreement is part of a broader strategy to address key challenges in chronic disease management by improving patient access to innovative treatments.

The implementation timeline for the co-marketing of the Semaglutide Injection has not been specified in the filing. However, both companies are expected to leverage their respective strengths to ensure the product reaches the target market efficiently. The agreement signifies a strategic collaboration between two major players in the pharmaceutical industry, focusing on enhancing patient care in India.

Torrent Pharmaceuticals Ltd is a specialty-focused global pharmaceutical company with a strong presence in chronic and sub-chronic therapies. The company operates in more than 50 countries and is ranked No. 1 among Indian pharmaceutical companies in Brazil and Germany. Torrent Pharma has invested significantly in R&D infrastructure, employing over 750 scientists.

Zydus Lifesciences Ltd is an innovation-led global life sciences company with leadership positions across pharmaceuticals and consumer wellness. The company is supported by an emerging MedTech franchise and has a strong international presence across the United States, India, and other global markets. Zydus is focused on unlocking new possibilities in life sciences through quality healthcare solutions.